To present at FNN Virtual Investor Event
Details of the virtual event can be found here. The presentation will feature an overview of Regeneus' business for new investors, including the Company's platform technologies and recent highlights, including the Kyocera collaboration and licensing agreement for Progenza OA for Japan.
To view the presentation, please visit:
About Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.